Ianchulev Amends Eyenovia Stake Filing
Ticker: HYPD · Form: SC 13D/A · Filed: Jul 18, 2024 · CIK: 1682639
| Field | Detail |
|---|---|
| Company | Eyenovia, INC. (HYPD) |
| Form Type | SC 13D/A |
| Filed Date | Jul 18, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, schedule-13d, ownership-change
Related Tickers: EYEN
TL;DR
Ianchulev updated his Eyenovia stake filing on 7/18. Watch for more details.
AI Summary
Tsontcho Ianchulev, through an amendment filed on July 18, 2024, has updated his Schedule 13D filing concerning Eyenovia, Inc. The filing indicates a change in the beneficial ownership of the company's common stock. The specific details of the change in ownership percentage or the exact number of shares are not explicitly stated in this excerpt, but the amendment signifies an ongoing reporting requirement for significant shareholders.
Why It Matters
This amendment signals a potential shift in control or significant shareholder activity for Eyenovia, Inc., which could influence its stock price and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position, which can lead to increased volatility.
Key Numbers
- 20240718 — Filing Date (Date of the Schedule 13D/A amendment filing)
Key Players & Entities
- Tsontcho Ianchulev (person) — Filing person and beneficial owner
- Eyenovia, Inc. (company) — Subject company
- 295 Madison Avenue, Suite 2400, New York, NY 10017 (address) — Business and mail address for Eyenovia, Inc. and filing person
FAQ
What specific change in beneficial ownership is reported in this Schedule 13D/A amendment?
This excerpt does not specify the exact change in beneficial ownership, only that an amendment to the Schedule 13D filing was made on July 18, 2024.
Who is the filing person for this Schedule 13D/A?
The filing person is Tsontcho Ianchulev.
What is the CUSIP number for Eyenovia, Inc. common stock?
The CUSIP number for Eyenovia, Inc. common stock is 30234E 104.
What is the business address of Eyenovia, Inc.?
The business address of Eyenovia, Inc. is 295 Madison Avenue, Suite 2400, New York, NY 10017.
What form is being filed?
A Schedule 13D/A (Amendment No. 7) is being filed.
Filing Stats: 1,180 words · 5 min read · ~4 pages · Grade level 10 · Accepted 2024-07-18 19:46:49
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securiti
Filing Documents
- tm2419796d1_sc13da.htm (SC 13D/A) — 40KB
- 0001104659-24-080929.txt ( ) — 42KB
Security and Issuer
Item 1. Security and Issuer There are no changes to the Item 1 information previously filed.
Identity and Background
Item 2. Identity and Background There are no changes to the Item 2 information previously filed.
Source and Amount of Funds or Other Consideration
Item 3. Source and Amount of Funds or Other Consideration There are no changes to the Item 3 information previously filed.
Purpose of Transaction
Item 4. Purpose of Transaction There are no changes to the Item 4 information previously filed.
Interest in Securities of the Issuer
Item 5. Interest in Securities of the Issuer (a)-(b) The aggregate number and percentage of Common Stock beneficially owned by the Reporting Person (on the basis of a total of 63,393,678 shares of Common Stock outstanding as of July 2, 2024) are as follows: a) Amount beneficially owned: 2,078,437 Percentage: 3.2% b) Number of shares to which the Reporting Person has: i. Sole power to vote or to direct the vote: 1,465,770 (1) ii. Shared power to vote or to direct the vote: 612,667 (2) iii. Sole power to dispose or to direct the disposition of: 1,465,770 (1) iv. Shared power to dispose or to direct the disposition of: 612,667 (2) (1) Includes (i) 348,452 shares of Common Stock, (ii) 1,055,495 shares of Common Stock underlying options that are exercisable within 60 days of the date of this report and (iii) 61,823 shares of Common Stock underlying warrants held by Dr. Ianchulev directly that are exercisable within 60 days of the date of this report. (2) Includes (i) 6,000 shares of Common Stock held by The Meliora Trust and (ii) 606,667 shares of Common Stock held by Private Medical Equity, Inc. Dr. Ianchulev is a trustee and beneficiary of the Meliora Trust and therefore may be deemed to have beneficial ownership of the shares of Common Stock held by The Meliora Trust. Dr. Ianchulev is one of the two principal shareholders of Private Medical Equity, Inc. and, therefore, may be deemed to have beneficial ownership of the shares of Common Stock held by Private Medical Equity, Inc. (c) Each of the required transactions described in this Item 5(a) were reported on Forms 4 filed by Dr. Ianchulev with the SEC pursuant to Section 16 of the Act and are available on the SEC’s website at www.sec.gov. The information reported in such filings is expressly incorporated herein. (d) Not applicable. (e) As of July 2, 2024, the Reporting Person ceased to be the beneficial owner of more than 5% of the Issuer’s outstanding shares of Com
Contracts, Arrangements, Understandings or Relationships
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer There are no changes to the Item 6 information previously filed. CUSIP No. 30234E 104 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: July 18, 2024 /s/ Tsontcho Ianchulev Tsontcho Ianchulev